Safety and Efficacy of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Focal Segmental Glomerulosclerosis, Treatment-Resistant Minimal Change Disease, or Diabetic Nephropathy: TRACTION-2 Trial Design

Kidney International Reports - Tập 6 - Trang 2575-2584 - 2021
Liron Walsh1, John F. Reilly1, Caitlin Cornwall1, Gregory A. Gaich1, Debbie S. Gipson2, Hiddo J.L. Heerspink3, Leslie Johnson1, Howard Trachtman4, Katherine R. Tuttle5,6, Youssef M.K. Farag1, Krishna Padmanabhan7, Xin-Ru Pan-Zhou1, James R. Woodworth1, Frank S. Czerwiec1
1Goldfinch Bio, Inc., Cambridge, Massachusetts, USA
2University of Michigan, Ann Arbor, Michigan, USA
3University of Groningen, Groningen, Netherlands
4NYU Langone Health, New York, New York, USA
5Providence Health Care, Spokane, WA
6University of Washington, Seattle, Washington, USA
7Cytel, Waltham, Massachusetts, USA

Tài liệu tham khảo

Thông tin
Thông tin xuất bản

Kidney International Reports

Tập 6

2575-2584

Thông tin tác giả